{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:46:59Z","timestamp":1767134819020,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":110,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003181","type":"reference-entry","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T22:18:21Z","timestamp":1069366701000},"source":"Crossref","is-referenced-by-count":8,"title":["Bile acids for viral hepatitis"],"prefix":"10.1002","author":[{"given":"W","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,4,22]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD003181-BIB1|cit1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00004836-199803000-00009","article-title":"Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid","volume":"26","author":"Abdelmalek","year":"1998","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD003181-BIB3|cit2","unstructured":"Angelico M Gandin C Pescarmona E Rapicetta M Del Vecchio C Goffredo F Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial Italian Journal of Gastroenterology 1993 446"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB2|cit3","first-page":"263","article-title":"Recombinant interferon alpha and ursodeoxycholic acid versus interferon alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up","volume":"90","author":"Angelico","year":"1995","journal-title":"The American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003181-BIB4|cit4","first-page":"427","article-title":"Effect of tauroursodeoxycholic acid on ALT, GGT and viral load in patients with hepatitis C virus-related chronic hepatitis with reference to the genotype","volume":"31","author":"Belloni","year":"1999","journal-title":"The Italian Journal of Gastroenterology and Hepatology"},{"issue":"4 Pt.2","key":"10.1002\/14651858.CD003181-BIB5|cit5","first-page":"403A","article-title":"Interferon alfa and ursodeoxycholic acid combination versus interferon alone in the treatment of chronic hepatitis C: Results of a randomized trial [AASLD abstract]","volume":"24","author":"Bonnand","year":"1996","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003181-BIB7|cit6","unstructured":"Boucher E Andre P Jouanolle H Moirand R Guyader D Ruffault A Treatment of chronic viral C hepatitis by interferon plus ursodeoxycholic acid: results from a controlled randomized trial in 80 patients Hepatology 1994 169A"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB6|cit7","first-page":"322","article-title":"Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients","volume":"21","author":"Boucher","year":"1995","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003181-BIB8|cit8","first-page":"127","article-title":"One year ursodeoxycholic acid treatment of chronic viral hepatitis in heart transplanted patients: results of a prospective double-blind placebo randomized controlled study in 60 patients","volume":"25","author":"Cadranel","year":"1996","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003181-BIB9|cit9","first-page":"S102","article-title":"Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis","volume":"21","author":"Clerici","year":"1994","journal-title":"Journal of Hepatology"},{"issue":"23","key":"10.1002\/14651858.CD003181-BIB10|cit10","first-page":"1624","article-title":"Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study","volume":"45","author":"Crosignani","year":"1998","journal-title":"Hepato-Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003181-BIB11|cit11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00042737-200012050-00006","article-title":"Efficacy of ursodeoxycholic acid in association with interferon alpha for chronic hepatitis C in interferon alpha non-responder patients","volume":"12","author":"Fabbri","year":"2000","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD003181-BIB12|cit12","unstructured":"Fabri C Mazzella G Marchetto A Pezzoli E Accogli P Fusaroli F Efficacy of ursodeoxycholic acid administration as adjuvant therapy together with alfa-interferon for chronic hepatitis C Journal of Hepatology 1997 S179"},{"issue":"3","key":"10.1002\/14651858.CD003181-BIB13|cit13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00004836-199904000-00013","article-title":"Effect of ursodeoxycholic acid in acute viral hepatitis","volume":"28","author":"Galsk\u00fd","year":"1999","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003181-BIB14|cit14","first-page":"338","article-title":"Combined interferon and ursodeoxycholic acid therapy in 48 chronic hepatitis C patients","volume":"5","author":"Ge","year":"1997","journal-title":"Journal of New Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB15|cit15","first-page":"32","article-title":"Ursodeoxycholic acid therapy in chronic hepatitis C patients","volume":"5","author":"Huang","year":"1997","journal-title":"Acta Academic Medicine CPAPF (Chinese People Armed Police Force)"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB16|cit16","first-page":"363A","article-title":"Efficacy of combination therapy of interferon with ursodeoxycholic acid in chronic hepatitis C: sustained clearance of viremia after interferon discontinuation","volume":"20","author":"Kawata","year":"1994","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB17|cit17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/BF01213297","article-title":"Efficacy of combination therapy of interferon alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial","volume":"32","author":"Kiso","year":"1997","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003181-BIB18|cit18","first-page":"15","article-title":"Ursodeoxycholic acid, interferon-alfa, versus interferon-alfa + ursodeoxycholic acid in chronic C hepatitis","volume":"9","author":"Leri","year":"1994","journal-title":"Mediterranean Journal of Infectious and Parasitic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD003181-BIB19|cit19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0011-393X(05)80802-1","article-title":"Effect of therapy with combined interferon and tauroursodeoxycholic acid in chronic hepatitis C: biochemical and virologic evaluation","volume":"55","author":"Picciotto","year":"1994","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD003181-BIB20|cit20","first-page":"A16","article-title":"Interferon sparing effect of adjuvant tauro-ursodeoxycholic acid for treatment of chronic hepatitis C: result on liver histology","volume":"40","author":"Pigozzi","year":"1997","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD003181-BIB21|cit21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1080\/003655200750023624","article-title":"Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon","volume":"35","author":"Poupon","year":"2000","journal-title":"Scandinavia Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB22|cit22","first-page":"151","article-title":"Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease","volume":"7","author":"Puoti","year":"1995","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD003181-BIB23|cit23","doi-asserted-by":"crossref","unstructured":"Puoti C Pannullo A Annovazzi G Filippi T Magrini A Ursodeoxycholic acid and chronic hepatitis C infection The Lancet 1993 1413 4","DOI":"10.1016\/0140-6736(93)90981-L"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB24|cit24","first-page":"48","article-title":"The effeicacy of ursodeoxycholic acid on chronic hepatitis","volume":"14","author":"Qing","year":"1999","journal-title":"Journal of North Sichuan Medical College"},{"key":"10.1002\/14651858.CD003181-BIB25|cit25","first-page":"168","article-title":"The ursodeoxycholic acid for the treatment of HCV infections","volume":"3","author":"Scotto","year":"1997","journal-title":"Infezioni in Medicine"},{"issue":"7","key":"10.1002\/14651858.CD003181-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1023\/A:1018854424403","article-title":"Long-term efficacy of interferon alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis","volume":"42","author":"Senturk","year":"1997","journal-title":"Digestive Diseases and Sciences"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/0270-9139(94)90683-1","article-title":"A multi-center randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C","volume":"19","author":"Takano","year":"1994","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD003181-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1440-1746.1996.tb01844.x","article-title":"Efficacy of ursodeoxycholic acid in combination with interferon alpha in treating chronic hepatitis C: results of a long-term follow-up trial","volume":"11","author":"Tanaka","year":"1996","journal-title":"Journal of Gastroenterology & Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD003181-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/00042737-199910000-00002","article-title":"Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients","volume":"11","author":"Tsubota","year":"1999","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"4 Pt.2","key":"10.1002\/14651858.CD003181-BIB30|cit30","first-page":"594A","article-title":"Predictive factors of non-response to recombinant interferon alfa 2b in patients with chronic hepatitis C (AASLD abstract)","volume":"24","author":"Viola","year":"1996","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB31|cit31","first-page":"290A","article-title":"A randomized controlled trial of 12-month treatment with interferon alfa 2b and ursodeoxycholic acid for chronic hepatitis C","volume":"28","author":"Viola","year":"1998","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003181-BIB32|cit32","first-page":"148","article-title":"Efficacy of ursodeoxycholic acid therapy on chronic hepatitis","volume":"11","author":"Zhou","year":"1995","journal-title":"Journal of Clinical Hepato-Biliary Diseases"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB33|cit33","first-page":"237","article-title":"Efficacy of ursodeoxycholic acid therapy on chronic hepatitis C","volume":"14","author":"Zhu","year":"1994","journal-title":"Bulletin of Nantong Medical College"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003181-BIB34|cit34","first-page":"120A","article-title":"Interferon-alpha and tauroursodeoxycholic acid in chronic hepatitis C: a novel therapeutic combination (AASLD abstract)","volume":"22","author":"Angelico","year":"1995","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003181-BIB35|cit35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0168-8278(94)80001-4","article-title":"The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis","volume":"20","author":"Attilli","year":"1994","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003181-BIB36|cit36","first-page":"635","article-title":"Long-term treatment with ursodeoxycholic acid in patients with chronic active hepatitis","volume":"50","author":"Buzzelli","year":"1991","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD003181-BIB37|cit37","first-page":"537","article-title":"Ursodeoxycholic acid-hemisuccinate in the treatment of chronic active hepatitis. A controlled clinical study","volume":"83","author":"Buzzelli","year":"1992","journal-title":"Minerva medica"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB38|cit38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hep.1840130222","article-title":"Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study","volume":"13","author":"Crosignani","year":"1991","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003181-BIB39|cit39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1386-6346(98)00070-9","article-title":"Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a multicentre dose-response study","volume":"13","author":"Crosignani","year":"1998","journal-title":"Hepatology Research"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB40|cit40","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/030006058201000416","article-title":"Safe use of ursodeoxycholic acid in the treatment of dyspeptic symptoms in patients with chronic active hepatitis: A double-blind controlled trial","volume":"10","author":"Vecchio Blanco","year":"1982","journal-title":"The Journal of international medical research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003181-BIB41|cit41","first-page":"S32","article-title":"UDCA improves serum liver enzymes but not liver histology in chronic hepatitis","volume":"11","year":"1990","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB42|cit42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004836-199703000-00021","article-title":"Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B","volume":"24","author":"Kadayifci","year":"1997","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB43|cit43","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1440-1746.1995.tb01596.x","article-title":"Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C","volume":"10","author":"Lu","year":"1995","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD003181-BIB44|cit44","first-page":"359","article-title":"Effect of therapy with bis-hemisuccinate of ursodeoxycholic acid bisodic salt in patients with chronic liver diseases","volume":"83","author":"Pinto","year":"1992","journal-title":"Minerva medica"},{"issue":"12","key":"10.1002\/14651858.CD003181-BIB45|cit45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF01536665","article-title":"Effect of different doses of ursodeoxycholic acid in chronic liver disease","volume":"34","author":"Podda","year":"1989","journal-title":"Digestive Diseases and Sciences"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0016-5085(90)90032-V","article-title":"Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis","volume":"98","author":"Podda","year":"1990","journal-title":"Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003181-BIB47|cit47","doi-asserted-by":"crossref","first-page":"120A","DOI":"10.1016\/0270-9139(95)94204-1","article-title":"Tauroursodeoxycholic acid for the treatment of chronic hepatitis: A dose-response study (AASLD abstract)","volume":"22","author":"Podda","year":"1995","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003181-BIB48|cit48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0011-393X(05)80659-9","article-title":"Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis","volume":"53","author":"Portincasa","year":"1993","journal-title":"Current Therapeutic Research"},{"issue":"5","key":"10.1002\/14651858.CD003181-BIB49|cit49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00315225","article-title":"Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis","volume":"40","author":"Rolandi","year":"1991","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB50|cit50","first-page":"106","article-title":"The effect of UDCA on 42 chronic hepatitis patients with persisting high level of gamma GT","volume":"8","author":"Song","year":"1998","journal-title":"Chinese Journal of Intergretive Traditional and Western Medicine on Liver Diseases"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB51|cit51","first-page":"44","article-title":"Combination of UDCA, Bing Du Zuo, and Ju Jibao for the treatment on 53 chronic hepatitis C patients (Chinese)","volume":"20","author":"Zhu","year":"1997","journal-title":"Bulletin of Jiamusi Medical College"},{"issue":"6","key":"10.1002\/14651858.CD003181-BIB52|cit52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/0958-1669(95)80113-8","article-title":"Interferon-beta treatment of human disease","volume":"6","author":"Alam","year":"1995","journal-title":"Current Opinion in Biotechnology"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB53|cit53","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0022-2275(20)38175-X","article-title":"The hydrophobic-hydrophilic balance of bile salt. Inverse correlation between reversephase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities","volume":"23","author":"Armstrong","year":"1982","journal-title":"Journal of Lipid Research"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB54|cit54","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.1840100404","article-title":"Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis","volume":"10","author":"Batta","year":"1989","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB55|cit55","first-page":"322","article-title":"Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral hepatitis: results from a controlled randomized trial in 80 patients","volume":"21","author":"Boucher","year":"1995","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB56|cit56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0950-3528(96)90010-X","article-title":"Hepatitis B and C viruses and primary liver cancer","volume":"10","author":"Brechot","year":"1996","journal-title":"Baillieres Clinical Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB57|cit57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep.1840110104","article-title":"Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid","volume":"11","author":"Calmus","year":"1990","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003181-BIB58|cit58","article-title":"Bile acids for viral hepatitis (Protocol for a Cochrane Review)","author":"Chen","year":"2001","journal-title":"The Cochrane Library"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB59|cit59","article-title":"Bile acids for primary sclerosing cholangitis (Protocol for a Cochrane Review)","author":"Chen","year":"2002","journal-title":"The Cochrane Library"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB60|cit60","article-title":"Bile acids for primary sclerosing cholangitis","author":"Chen","year":"2003","journal-title":"The Cochrane Library"},{"issue":"8","key":"10.1002\/14651858.CD003181-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/gut.30.8.1110","article-title":"Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment","volume":"30","author":"Chretien","year":"1989","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB62|cit62","article-title":"Cochrane Reviewers' Handbook 4.1.4 [updated October 2001]","author":"Clake","year":"2001","journal-title":"The Cochrane Library"},{"issue":"3","key":"10.1002\/14651858.CD003181-BIB63|cit63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003181-BIB64|cit64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"7109","key":"10.1002\/14651858.CD003181-BIB65|cit65","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD003181-BIB66|cit66","first-page":"2596","article-title":"Chronic hepatitis C: how to recognize, when to treat","volume":"37","author":"Fallon","year":"1997","journal-title":"Consultant"},{"key":"10.1002\/14651858.CD003181-BIB67|cit67","first-page":"4(i","article-title":"Management of hepatitis C","volume":"Suppl","author":"Farrell","year":"1999","journal-title":"Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB68|cit68","first-page":"77","article-title":"Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B","volume":"21","author":"Fattovich","year":"1995","journal-title":"Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD003181-BIB69|cit69","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1053\/jhep.2002.36810","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003181-BIB70|cit70","first-page":"223","article-title":"Metabolism of bile acids","volume-title":"Oxford Textbook of Clinical Hepatology","volume":"1","author":"Fuchs","year":"1999"},{"issue":"5","key":"10.1002\/14651858.CD003181-BIB71|cit71","first-page":"421","article-title":"Tauro-ursodeoxycholic acids vs ursodeoxycholic acid in the dissolution of biliary calculi. Result of a single blind study","volume":"143","author":"Gallo","year":"1993","journal-title":"La Clinica Terapeutica"},{"key":"10.1002\/14651858.CD003181-BIB72|cit72","first-page":"322","article-title":"Alcoholic hepatitis: no glucocorticosteroids?","volume-title":"Steatohepatitis (NASH and ASH)-Falk Symposium 121","author":"Gluud","year":"2001"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB73|cit73","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","author":"Gluud","year":"2002","journal-title":"The Cochrane Library"},{"issue":"9184","key":"10.1002\/14651858.CD003181-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB75|cit75","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1053\/jhep.2002.32931","article-title":"Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways","volume":"35","author":"Guicciardi","year":"2002","journal-title":"Hepatology"},{"issue":"24","key":"10.1002\/14651858.CD003181-BIB76|cit76","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1002\/1097-0258(20001230)19:24<3325::AID-SIM827>3.0.CO;2-D","article-title":"Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies","volume":"19","author":"Hahn","year":"2000","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003181-BIB77|cit77","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM199701303360507","article-title":"The treatment of chronic viral hepatitis","volume":"336","author":"Hoffnagle","year":"1997","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003181-BIB78|cit78","volume-title":"Code of Federal Regulations & International Conference on Harmonization Guidelines","year":"1997"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB79|cit79","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/toxsci\/65.2.166","article-title":"Mechanisms of hepatotoxicity","volume":"65","author":"Jaeschke","year":"2002","journal-title":"Toxicological Sciences"},{"issue":"11","key":"10.1002\/14651858.CD003181-BIB80|cit80","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB81|cit81","article-title":"Ribavirin with or without alpha interferon versus no intervention, placebo or alpha interferon for chronic hepatitis C","author":"Kjaergard","year":"2002","journal-title":"The Cochrane Library"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB82|cit82","article-title":"Ribavirin with or without alpha interferon for chronic hepatitis C","author":"Kjaergard","year":"2002","journal-title":"The Cochrane Library"},{"issue":"5","key":"10.1002\/14651858.CD003181-BIB83|cit83","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB84|cit84","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2036.1997.124295000.x","article-title":"Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study","volume":"11","author":"Larghi","year":"1997","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD003181-BIB85|cit85","first-page":"2 (i-viii)","article-title":"Management of chronic hepatitis B","volume":"Supplement","author":"Liaw","year":"1999","journal-title":"Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB86|cit86","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1142\/S0192415X0200017X","article-title":"Misuse of randomization: a review of Chinese randomized trials of herbal medicines for chronic hepatitis B","volume":"30","author":"Liu","year":"2002","journal-title":"American Journal of Chinese Medicine"},{"issue":"6","key":"10.1002\/14651858.CD003181-BIB87|cit87","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1053\/jhep.2001.29401","article-title":"Chronic hepatitis B","volume":"34","author":"Lok","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB88|cit88","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0300-5089(21)00714-8","article-title":"Drug-related acute and chronic hepatitis","volume":"9","author":"Maddrey","year":"1980","journal-title":"Clinical Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003181-BIB89|cit89","first-page":"C47","article-title":"Current and future treatment of hepatitis C","volume":"20","author":"Manns","year":"2001","journal-title":"Indian Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD003181-BIB90|cit90","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/hep.510250340","article-title":"Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype","volume":"25","author":"Mihm","year":"1997","journal-title":"Hepatology"},{"issue":"9128","key":"10.1002\/14651858.CD003181-BIB91|cit91","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervetion efficacy reported in meta-analyses","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB92|cit92","article-title":"Interferon for acute hepatitis C","author":"Myers","year":"2002","journal-title":"The Cochrane Library"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB93|cit93","article-title":"Interferon for interferon naive patients with chronic hepatitis C","author":"Myers","year":"2002","journal-title":"The Cochrane Library"},{"issue":"2","key":"10.1002\/14651858.CD003181-BIB94|cit94","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/hep.1840120221","article-title":"Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration","volume":"12","author":"Nakagawa","year":"1990","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB95|cit95","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/archinte.1972.03650040130012","article-title":"Bile acids, liver injury and liver disease","volume":"130","author":"Palmer","year":"1972","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003181-BIB96|cit96","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholiic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003181-BIB97|cit97","first-page":"I","article-title":"Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a dose-response study (IASL Abstract)","volume":"23","author":"Podda","year":"1996","journal-title":"Hepatology"},{"issue":"9055","key":"10.1002\/14651858.CD003181-BIB98|cit98","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB99|cit99","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1053\/jhep.2002.32533","article-title":"Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes","volume":"35","author":"Qiao","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB100|cit100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-2008-1040523","article-title":"Side effects of alpha interferon","volume":"9","author":"Renault","year":"1989","journal-title":"Seminar in Liver Disease"},{"key":"10.1002\/14651858.CD003181-BIB101|cit101","first-page":"417","article-title":"Hepatitis delta virus disease","volume":"8","author":"Rizzetto","year":"1986","journal-title":"Progress in Liver Disease"},{"issue":"3","key":"10.1002\/14651858.CD003181-BIB102|cit102","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2893.2000.00219.x","article-title":"Apoptotic cell death does not parallel other indicators of liver damage in chronic hepatitis C patients","volume":"7","author":"Rodrigues","year":"2000","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"10.1002\/14651858.CD003181-BIB103|cit103","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD003181-BIB104|cit104","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/hep.1840360702","article-title":"National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003181-BIB105|cit105","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.1840040416","article-title":"Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties","volume":"4","author":"Sholmerich","year":"1984","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003181-BIB106|cit106","first-page":"790","article-title":"Hepatitis A and Hepatitis E","volume-title":"Infectious Disease","author":"Stapleton","year":"1994"},{"key":"10.1002\/14651858.CD003181-BIB107|cit107","unstructured":"WHO Hepatitis B Fact Sheet WHO\/204, www.who.int\/inf-fs\/en\/fact204.html"},{"key":"10.1002\/14651858.CD003181-BIB108|cit108","unstructured":"WHO Hepatitis C Fact Sheet WHO\/164, www.who.int\/inf-fs\/en\/fact164.html"},{"key":"10.1002\/14651858.CD003181-BIB109|cit109","first-page":"827","article-title":"The viruses of hepatitis","volume-title":"Oxford Textbook of Clinical Hepatology","volume":"1","author":"Wolfram","year":"1999"},{"key":"10.1002\/14651858.CD003181-BIB110|cit110","volume-title":"Viral Hepatitis","author":"Zuckermann","year":"1993"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003181.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T00:00:00Z","timestamp":1192579200000}}],"container-title":["The Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T07:24:57Z","timestamp":1734161097000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003181"}},"subtitle":[],"editor":[{"given":"Wendong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2002,4,22]]},"references-count":110,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003181","relation":{},"subject":[],"published":{"date-parts":[[2002,4,22]]}}}